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Bulk cell density and Wnt/TGFbeta signalling
regulate mesendodermal patterning of human
pluripotent stem cells
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In vitro differentiation of human pluripotent stem cells (hPSCs) recapitulates early aspects of
human embryogenesis, but the underlying processes are poorly understood and controlled.
Here we show that modulating the bulk cell density (BCD: cell number per culture volume)
deterministically alters anteroposterior patterning of primitive streak (PS)-like priming. The
BCD in conjunction with the chemical WNT pathway activator CHIR99021 results in distinct
paracrine microenvironments codifying hPSCs towards deﬁnitive endoderm, precardiac or
presomitic mesoderm within the ﬁrst 24 h of differentiation, respectively. Global gene
expression and secretome analysis reveals that TGF superfamily members, antagonist of
Nodal signalling LEFTY1 and CER1, are paracrine determinants restricting PS progression.
These data result in a tangible model disclosing how hPSC-released factors deﬂect
CHIR99021-induced lineage commitment over time. By demonstrating a decisive, functional
role of the BCD, we show its utility as a method to control lineage-speciﬁc differentiation.
Furthermore, these ﬁndings have profound consequences for inter-experimental compar-
ability, reproducibility, bioprocess optimization and scale-up.
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H
uman pluripotent stem cells (hPSCs), including embryo-
nic (hESCs) and induced pluripotent stem cells, provide
an attractive model to study early aspects of human
embryogenesis in vitro, which are not assessable in vivo. More-
over, due to their growth and differentiation potential, hPSCs
constitute a well-characterized, generally unlimited cell source for
the mass generation of lineage- and possibly patient-speciﬁc
progenies. This opens new avenues for regenerative cell
therapies and superior drug discovery approaches. hPSC-based
modelling of early human development and the large-scale
production of lineage-speciﬁc progenies will both depend on
well-deﬁned, highly reproducible culture and differentiation
conditions1.
We and others recently showed that hPSCs can be expanded as
cell-only aggregates in suspension culture2–4, thereby providing a
ﬂexible strategy for process optimization and scale-up. It enables
extensive parameter permutation in multiwell dishes, simple
expansion in Erlenmeyer ﬂasks and ultimately transition to more
sophisticated, stirred tank bioreactors5–7.
Initiating differentiation, per deﬁnition, turns PSC aggregates
into embryoid bodies (EBs) wherein a wide variety of cell types
can form. It is generally thought that tissue differentiation in EBs
occurs in a disorganized fashion8. However, work on mouse EBs
showed that the supplementation of external growth factors, such
as the WNT pathway agonist Wnt3a, mediates the execution of
self-reinforcing, gastrulation-like processes in EBs displaying a
high degree of self-organization9.
During gastrulation, cells are allocated into the three germ
layers in an ordered spatiotemporal sequence. Epiblast cells
located at the interior of the embryo migrate to form the
deﬁnitive endoderm on the outside of the embryo proper and the
mesoderm between the endoderm and the epiblast. It is well
established that the spatial patterning during gastrulation in
mouse embryos is under the control of the Activin-Nodal, BMP
and WNT pathways, which can also be manipulated to direct
mouse and hESCs into derivatives of all three germ layers10–13.
However, controlling the complex pathways’ interplay during
PSC differentiation is challenging. It depends on the concentra-
tion of respective growth factor combinations as well as their
temporal supplementation patterns, and is often accompanied by
the heterogeneity of differentiation outcomes lacking inter-
experimental reproducibility14.
Using cardiomyogenic differentiation as central reference point
downstream of primitive streak (PS)-like priming, we have
focused on modulating the bulk cell density (BCD) deﬁned as the
number of hPS cells per medium volume in a respective culture
vessel. From a practical perspective, changes of the BCD in
conjunction with the GSK3 inhibitor CHIR99021 (CHIR)15 can
be used as a simple method to direct PS-like patterning into
deﬁnitive endoderm, precardiac mesoderm (PCM) or presomitic
mesoderm (PSM).
We show that BCD modulation only, within the ﬁrst 24 h,
results in distinct gene and protein expression patterns equivalent
to speciﬁc cell fates along a PS-like anteroposterior axis.
Secretome analysis reveals that the BCD effect is mediated via
distinct, time-dependent medium conditioning. Functional
analysis of secreted candidate factors unravelled that transform-
ing growth factor beta (TGFb) family members, Nodal signalling
antagonists LEFTY1 (left-right determination factor 1) and
CERBERUS (CER1) that are either expressed readily at the
pluripotent hPSC state or differentially upregulated in response to
CHIR, respectively, play decisive roles in PS-like determination of
hPSC, reminiscent of their function in mouse embryogenesis16.
By putting into perspective the impact of the BCD, the CHIR
concentration and the incubation time, our data highlight the
necessity to closely monitor the BCD, particularly at the earliest
stages of differentiation, to ensure desired lineage speciﬁcation
and process reproducibility.
Results
BCD and CHIR determine differentiation outcome within 24h.
Single-cell inoculation resulted in highly reproducible aggregate
formation withB1 106 cells per well in 12-well format (Supple-
mentary Fig. 1a,b) maintaining pluripotency marker expression
(Supplementary Fig. 1c), as shown before2,6.
Differentiation was induced by chemical WNT pathway
modulation17,18 with equal cell numbers per well at initiation.
Dissecting the protocol into an early stage (day 0–day 1; 24 h
CHIR supplementation) and a late stage (day 1–day 10), two
factors, the CHIR concentration and the culture medium volume
(deﬁning the BCD), were modiﬁed and cardiomyogenesis was
monitored at day 10 by NKX2.5-GFP expression19. Transgene
expression was highly dependent on the CHIR concentration
during the ﬁrst 24 h, as expected17. BCD changes at the late stage
had no apparent impact (Supplementary Fig. 1d), whereas
modulations during the ﬁrst 24 h had profound consequences.
In 1ml medium per well (BCD: 1 106 cells per ml) higher CHIR
concentrations were concomitant with increased green ﬂuore-
scent protein (GFP) expression (CHIR optimum at 15 mM; Fig. 1b
and Supplementary Fig. 1e). Vice versa, in 3ml medium per well
(BCD: 0.33 106 cells per ml), GPF was highest at 7.5 mM CHIR
with decreasing levels along increasing CHIR concentrations. In
2ml per well (BCD: 0.5 106 cells per ml), GFP expression
peaked at intermediate CHIR concentrations of 10–12.5 mM. GFP
levels correlated with overall cell counts on day 10 (Supple-
mentary Fig. 1f) as noted before17.
For detailed investigations, four cornerstone conditions were
deﬁned (Fig. 1b): two representing high NKX2.5-GFP (efﬁcient
cardiomyogenesis): 7.5 mM CHIR in 3ml (7.5/3; tagged in light
green) and 15 mM CHIR in 1ml (15/1; dark green); and two
representing low NKX2.5-GFP: 7.5 mM in 1ml (7.5/1; blue) and
15 mM in 3ml (15/3; red). Figure 1c depicts GFP assessment of 11
independent repeats for every condition, revealing the grade
of experimental variability; the average amount of GFPþ was
59.3±4.4% (7.5/3), 45.8±5.9% (15/1), 6.7±2.6% (7.5/1) and
20.0±7.3% (15/3), respectively.
Flow cytometry speciﬁc to the cardiomyocyte markers cardiac
myosin heavy chain, cardiac troponin T and sarcomeric actinin
conﬁrmed NKX2.5-GFP results, showing B67–74% positivity
for 7.5/3 and 15/1, and o15% positive cells for 7.5/1 and 15/3
conditions (Fig. 1d). Conversely, relative high contents of CD90-
and vimentin-expressing cells (31.0–47.4%) were found at 7.5/1
and 15/3 (Supplementary Fig. 1g), suggesting a ﬁbroblast-like
phenotype of non-cardiomyocytes.
Effect of BCD is platform-independent. Instead of modulating
the medium volume at constant cell counts per well (illustrated in
Fig. 1e(A)) the cell count per well was modiﬁed at equal medium
volume (Fig. 1e(B)) and agitation was applied during CHIR
exposure (Fig. 1e(B)—agitated) to verify that the ‘volume effect’
described above is indeed tantamount to the BCD rather than the
formation of volume-induced gradients or the like. At 7.5/3 and
15/1 conditions, the highest GFP levels were observed by all
experimental variations, strongly supporting that BCD-directed
differentiation is platform-independent. Furthermore, differ-
entiation in two-dimensional (2D) monolayer showed an equi-
valent BCD-dependent GFP pattern reﬂecting the three-dimen-
sional (3D) aggregate approach (Fig. 1f). Together, this indicates
the key impact of BCD modulation during the ﬁrst 24 h of
differentiation irrespective of the culture platform, prompting
investigations into the early stages of differentiation.
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Cornerstone-speciﬁc mesendodermal patterns on day 3.
Epithelial-to-mesenchymal transition of hPSCs and induction of
mesoderm commitment can be monitored by the reciprocal
epithelial cell adhesion molecule (EpCAM; CD326) to neural cell
adhesion molecule (NCAM; CD56) pattern20,21. The mesodermal
marker NCAM was upregulated 2–3 days after addition of CHIR
(Supplementary Fig. 2a), which was accompanied by down-
regulation of pluripotency-associated EpCAM (Fig. 2a). On day 3
the lowest NCAMþ levels of 11.3±8.5% were observed at
7.5/1, highest of 79.8±4.3% at 15/3 and intermediate levels
of 45.1±8.3% and 51.4±8.9% at 7.5/3 and 15/1, respectively
(Fig. 2a,b). The NCAMþ levels increased until day 10 to 480%
at 7.5/3, 15/1 and 15/3 but remained o20% at 7.5/1
(Supplementary Fig. 2a).
cKITþ /CXCR4þ expression (characteristic of endodermal
progenitors22) revealed a reversed pattern, namely relatively high
proportion of 28±12% double-positive cells at 7.5/1 and nearly
absence (0.67±0.31%) at 15/3; cardio-inductive conditions
15/1 and 7.5/3 showed intermediate levels of 9.4±1.8% and
11.1±3.4%, respectively (Fig. 2c).
Thus, cardiogenic cornerstones showed a similar expression
pattern of early mesendoderm progenitors, while cells at
non-cardiogenic settings were primed into opposing directions
either typical of deﬁnitive endoderm (primed anterior to PCM
along the PS) in 7.5/1 or of PSM (speciﬁed posterior to PCM)
in 15/3.
Cornerstone-speciﬁc PS patterns are cell line-independent.
Flow cytometry directly after CHIR treatment revealed
BCD-dependent expression patterns of the PS markers
T brachyury (T) and MIX1 homeobox-like protein 1 (MIXL1).
Using a MIXL1-GFP reporter line23, distinct expression in 2D
and 3D was found, reﬂecting NCAM patterns on day 3 with
signiﬁcantly higher MIXL1-GFPþ at 15/3 (76.7±2.4%) but
signiﬁcantly lower levels at 7.5/1 (16.01±1.8%) as compared with
15/1 (56.8±1.6%) and 7.5/3 (48.72±2.7%; Fig. 2d,e). Equivalent
patterns were observed for T applying the NKX2.5-
GFP- (Fig. 2f,g) and four different human induced pluripotent
stem cell lines (Supplementary Fig. 2b) established by various
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Figure 1 | The CHIR-to-volume ratio during the ﬁrst 24 h dictates differentiation outcome. (a) Schematic of expansion and subsequent differentiation.
The medium volume of 1–3ml and consequently the BCD is only modulated between day 0–1. (b) Representative images of the differentiation on day 10
using the NKX2.5-GFP cell line. The cornerstone conditions are marked by a coloured rectangle. Scale bar, 1mm. (c) Analysis of NKX2.5-GFPþ on day 10 of
the four cornerstone conditions, n¼ 11 independent experiments. The mean is shown as black line. *Po0.01, evaluated by one-way analysis of variance with
post hoc Bonferroni analysis. (d) Representative histograms for NKX2.5-GFPþ and staining against structural cardiac markers on day 10 obtained by ﬂow
cytometry. (e) Schematic of experiment (left) and corresponding NKX2.5-GFPþ on day 10 (right) in standard conditions using identical cell numbers in
different volumes (A) and in identical volume with adapted cell numbers for static as well as agitated conditions (B). Bars represent mean±s.e.m. of n¼ 3
independent experiments. (f) Representative images of NKX2.5-GFP expression on day 10 of differentiation performed in 2D monolayer cultures. Scale bar,
1mm. See also Supplementary Fig. 1. NS, not signiﬁcant.
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reprogramming technologies (Supplementary Methods). This
conﬁrms manifestation of cornerstone-speciﬁc, cell line-
independent expression of PS markers readily at 24 h of
differentiation.
BCD predominates CHIR in global gene expression patterns.
Microarray analyses of cornerstone conditions and controls
(undifferentiated cells and CHIR-free differentiation) at 24 h were
conducted. Principal component analysis revealed clear
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separation of CHIR-treated versus control conditions (Fig. 2h).
Within the CHIR-treated group, cardio-inductive conditions
(light and dark green) did not spread into separate groups but
intermingled between the other extremes (blue and red).This
highlights manifestation of distinct global transcriptome patterns
readily after 24 h. Remarkably, Venn diagram analysis of42-fold
regulated genes (of treated compared with undifferentiated
hPSCs) revealed only 15 genes that were exclusive to cardio-
inductive conditions (Fig. 2i). Additional statistical testing
(Po0.01) showed only a single gene (LOC100133311) of sig-
niﬁcant differential expression at cardiogenic conditions. This
suggests that PCM is mainly speciﬁed by an intermediate
expression pattern along the PS rather than deﬁned by an
exclusive set of upregulated lineage speciﬁers, in line with recently
published spatially resolved transcriptomic data sets of the PS
state in mice and chicken embryos24,25 (Supplementary Fig. 2c,d).
The Venn diagram depicts a distinct overlap of 224 genes
between 7.5/3 and 15/3 conditions (representing BCD depen-
dence) compared with 101 genes exclusive to the overlap of 15/1
and 15/3 (representing CHIR dependence). This was conﬁrmed
by statistical testing (Po0.01) revealing 105 low BCD (that is,
high medium volume) versus 18 high CHIR-regulated genes. This
highlights the notion that the BCD effect dominates the impact of
the CHIR concentration at our experimental conditions. Gene
ontology analysis of 45-fold regulated genes showed a clear
association with early PS patterning, including anterior/posterior
speciﬁcation (Fig. 2j). Unbiased regional allocation of each
condition to the mouse epibast (E7.0) by zipcode mapping24
conﬁrmed an epiblast-like stage of the undifferentiated cells and
increasing anteroposterior progression along the PS axis at
increasing CHIR and medium volume conditions.
Hierarchical clustering of genes association with pluripotency,
PS formation and gastrulation (Fig. 2l) revealed the close relation
of 7.5/1 (blue) and 15/1 (dark green), further underlining that the
BCD predominates the CHIR concentration. The distant-most
pattern to undifferentiated cells at 15/3 was accompanied
by the most prominent downregulation of pluripotency markers,
including NANOG, SOX2, DPPA2 and DPPA4 (Fig. 2l).
Conversely, markers of PS progression MIXL1 and T were
upregulated most at 15/3 conﬁrming ﬂow cytometry results
(Fig. 2f,g) by the high level of MIXL1 and T correlation in
individual samples on transcriptional level (Fig. 2m). However,
15/3 conditions were also unique regarding a number of
upregulated genes, including MSGN1, PAX3, PAX7, HOXA3,
HOXB3, AXIN2, CDX1 and CDX2 (speciﬁc to PSM/paraxial
mesoderm26–28), as well as CCND2, SP5, SP8, MSX1, MSX2,
SOX9, PAX3 and PAX7 (markers of posterior neural plate border
formation26,29, Fig. 2l and Supplementary Fig. 2e displaying HOX
gene pattern). Upregulation of FOXF1 and LHX1 further suggests
a close relation of 15/3-primed cells to a lateral plate mesoderm-
like fate, which, in the embryo, is located posterior to cardiac and
anterior to paraxial mesoderm along the PS30,31.
Low expression of endoderm-related markers OTX2, HHEX
and SHISA2 at 15/3 reﬂects the absence of cKITþ /CXCR4þ
(Fig. 2c). Highest NANOG expression at 7.5/1 negatively
correlated with CDX2 expression separating 7.5/1 against 15/3;
this, again, is intermingled by 7.5/3 and 15/1 (Fig. 2n–p)
conﬁrming anteroposterior mesoderm patterning by NANOG/
CDX2 (ref. 28).
WNT activity is BCD-sensitive at 7.5 but not 15 lM CHIR.
Following conﬁrmation of CHIR stability over 48 h under
experimental conditions (Supplementary Fig. 4a), multiplex
arrays were applied for detailed status analysis of the WNT
pathway effector b-catenin32,33. A ﬁrst response was readily
detected after 2 h (120min) post CHIR exposure (Supplementary
Fig. 4b), preceding end-point patterns observed at 24 h
(1,440min; Supplementary Fig. 4b). Continuous increase in
signal activity interestingly suggests diminished negative feedback
of the WNT pathway in the presence of CHIR (Supplementary
Fig. 4b) conﬁrming other cell systems32,34.
Statistical analysis revealed minor impact of the BCD on the
b-catenin status at 15 mM CHIR (Fig. 3a–h) suggesting that
differential pattering of 15/1 versus 15/3 is largely independent of
WNT pathway activity. In contrast, comparison of 7.5/1 and 7.5/3
revealed signiﬁcantly higher b-catenin activity at 7.5/3 (low BCD;
Fig. 3). This suggests that canonical WNT pathway activity is
more sensitive to BCD-dependent feedback at lower CHIR
concentrations.
Differential accumulation of secreted factors after 24 h. Since
CHIR-dependent b-catenin activity alone cannot explain the
differentiation results, we postulated a role for CHIR/BCD-
dependent accumulation of secreted pathway modulators. This
idea is further suggested by the cornerstone-speciﬁc gene
expression patterns obtained for key paracrine modulators of
development (Supplementary Fig. 5a). To test the hypothesis that
differential secretomes direct PS patterning in our system, we
exchanged the entire medium after 6 h of CHIR treatment, but
maintaining respective CHIR/BCD conditions. This indeed
altered cardiomyogenesis at day 10, stressing the assertive impact
of secreted factors at very early differentiation stages (Fig. 4a). At
7.5/1, NKX2.5-GFPþ increased from 2.4±0.8 to 39.0±5.0%
(Fig. 4b). Conversely, at cardio-inductive conditions 7.5/3 and
15/1, GFPþ expression signiﬁcantly decreased from 450 to
o25%; yet at 15/3, GFPþ remained at 13–14%.
Figure 2 | Distinct mesendodermal identities are manifested within 24 h of differentiation. (a) Representative density plots for NCAM/EpCAM and
(b) analysis of NCAMþ of eight independent experiments on day 3. *Po0.05, evaluated by one-way analysis of variance (ANOVA) with post hoc
Bonferroni analysis. (c) Flow cytometric analysis for cKITþ/CXCR4þ of three independent experiments on day 3 (n¼ 3 independent experiments).
(d,e) Representative density plots showing MIXL1-GFP on day 1 in 2D monolayer (upper panel), 3D suspension (lower panel) and respective quantiﬁcation
in n¼ 5 independent experiments. *Po0.001, evaluated by one-way ANOVA with post hoc Bonferroni analysis. (f,g) Representative density plots showing
T-brachyury on day 1 from suspension-based differentiation and respective quantiﬁcation (n¼ 5 independent experiments). *Po0.05, evaluated by one-
way ANOVA with post hoc Bonferroni analysis. (h) Principal component analysis of microarray data. Each dot represents an independent sample collected
after 24 h of differentiation and undifferentiated hESCs. (i) Venn diagram of 42-fold regulated genes in the four conditions after 24 h compared with
undifferentiated cells. (j) Top-ranked gene ontology terms without pre-selection58 associated with 45-fold regulated gens in the four conditions.
(k) Spatial allocation of the each cornerstone condition to the mouse epiblast (E7.0) based on zipcode mapping of whole-transcriptome data along the
primitive streak. Red¼ high correlation; green¼ low correlation. (l) Heatmap of differentially regulated genes (Po0.001) associated with pluripotency,
primitive streak, early endoderm, early mesoderm and neural plate border. (m,n) Correlation of MIXL1/T-brachyury and NANOG/CDX2 in CHIR-treated
conditions. (o,p) Flow cytometric analysis of CDX2 and NANOG on day 1. n¼ 5 and 3 of independent experiments, respectively. *Po0.01 compared with
7.5mM conditions evaluated by one-way ANOVA with post hoc Bonferroni analysis. All bars shown in this ﬁgure represent mean±s.e.m. See also
Supplementary Figs 2 and 3. NS, not signiﬁcant.
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Supernatant analysis of secreted WNTs was exemplary
performed by a quantitative protein array (exemplarily shown
for DKK1 in Supplementary Fig. 5b) and conﬁrmed by western
blot (Supplementary Fig. 5c). Strikingly 46-fold higher concen-
trations of the WNT antagonist Dickkopf-1 (DKK1) was detected
in 3ml (low BCD) compared with respective 1ml settings
(Supplementary Fig. 5a–c). Accounting for the medium volume
418-fold higher DKK1 accumulation was found at 7.5/3 and
15/3 (low BCD) compared with 7.5/1 and 15/1, matching
respective gene expression data (Supplementary Fig. 5b, right).
In light of this, it was surprising that exogenous DKK1 supple-
mentation parallel to CHIR had no apparent impact on cardio-
myogenesis at any cornerstone condition (Fig. 4c and
Supplementary Fig. 5d). In contrast, the chemical DKK1 inhibitor
WAY-262611 (ref. 35) signiﬁcantly reduced NKX2.5-GFPþ
levels (Supplementary Fig. 5e,f). Assuming speciﬁcity of
WAY-262611, these ﬁndings might suggest that endogenous
DKK1, per se, is required for proper mesendoderm formation/
speciﬁcation in hPSCs equivalent to early embryogenesis36 but
supplementation of recombinant DKK was ineffective in modu-
lation differentiation in our system (Fig. 4c and Supplementary
Fig. 5d).
Expression of SFRP1, another secreted WNT antagonist,
showed a reversed pattern compared with DKK1, that is,
higher gene and protein levels at 1 versus 3ml (Supplementary
Fig. 5g,h), whereby highest SFRP1 levels at 7.5/1 and at non-
CHIR controls suggests its repression along CHIR-triggered
(posterior) progression of differentiation (Supplementary
Fig. 5a,g,h). However, recombinant SFRP supplementation
showed a minor effect in our experiments (Fig. 4c) equivalent
to DKK1 addition.
BMP pathway modulation provokes anteroposterior shifts.
Testing robustness of the cornerstone conditions to other estab-
lished modulators of hPSC differentiation and cardiomyogenesis
revealed remarkable stability to activin A, insulin or basic ﬁbro-
blast growth factor (bFGF) supplementation (Fig. 4c). In contrast,
BMP4 (but not BMP2) signiﬁcantly altered differentiation
(Fig. 4c–e), notably reﬂecting patterns of additional medium
exchange (Fig. 4a,b): NKX2.5-GFPþ increased at 7.5/1
(from 8.0±4.1 to 56.5±4.5%) but dropped at 7.5/3 and 15/1
(from 57.0±4.4% to 34.0±8.0% and 56.8±4.1% to 22.5±4.5%,
respectively; Fig. 4e). Combined with ﬁndings that MIXL1-GFPþ
increased across all cornerstones (Fig. 4f), overall posteriorization
by BMP4 is strongly suggested by this data.
BMP4 addition hardly perturbed the WNT pathway at the level
of b-catenin activity (Supplementary Fig. 6) but some reduction
was observed at 15/1 conditions suggesting a direct crosstalk
between the BMP and WNT pathways as previously published37.
Opposing BMP signalling by dorsomorphin38 resulted in signi-
ﬁcant NKX2.5-GFP reduction at 7.5/3 (Fig. 4g), suggesting
cornerstone conditions’ dependency on endogenous BMP
signalling and subsequent anteriorization towards 7.5/1-like
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conditions by dorsomorphin. Notably, dorsomorphin only
marginally affected 15/1 (Fig. 4g), which is opposed by the
signiﬁcant impact of BMP4 supplementation outlined above
(Fig. 4e).
BMP and WNT signalling (conducted through SMAD 1/5/8
and -catenin, respectively) converge in controlling mesendo-
derm speciﬁcation on the transcriptional level28,39. Since
antagonizing BMP by dorsomorphin hardly affected the 15/1
and 15/3 conditions, we have postulated their predominant WNT
dependence. Indeed, direct inhibition of WNT pathway activity
at the -catenin level by IWR1 supplementation (that is, by
promoting -catenin degradation via stabilization of AXIN)
increased NKX2.5-GFPþ levels at 15/3 (Fig. 4h) suggesting
expected cornerstone anteriorization towards PCM (that is,
adjustment of 15/3 towards 7.5/3-like conditions). Accordingly,
IWR1 disrupted cardiomyogenesis at 15/1, supposedly by
anteriorization towards 7.5/1-like conditions. Notably, supple-
mentation of the WNT inhibitor IWP2, a chemical inhibitor of
PORCUPINE, which acts by disrupting secretion of WNTs, did
not alter the cardiac differentiation outcome (Supplementary
Fig. 5i). This notably suggests a minor role of secreted WNTs in
specifying cornerstone conditions, in line with the vastly ineffec-
tive supplementation of DKK1 or SFRP1.
Together our results conﬁrm the established complexity of
the WNT and BMP signalling pathways’ interplay in deﬁning
cells’ distinct positioning along the PS28,39. At cornerstone
conditions, lacking extrinsic BMP supplementation, BMP
pathway activity is a result of both the CHIR concentration
and the BCD; vice versa BMP activity shapes PS patterning
(that is, promotes posteriorization) in a BCD-dependent
manner, including feedback on the CHIR-controlled WNT
pathway activity.
Secreted LEFTY1 and CER1 restrict posterior PS progression.
To further investigate BCD effects and their time dependence,
supernatants were collected at 6 or 24 h from 7.5/1 conditions
(most anterior PS speciﬁcation). Puriﬁed proteins were supple-
mented to 15/3 (most posterior) parallel to CHIR exposure
(Fig. 5a). The ‘6 h secretome’ elevated NKX2.5-GFPþ from
11.1±2.5 to 38.6±4.2%, suggesting the expected presence of
anteriorizing factors. This anteriorizing activity was surprisingly
reduced when supplementing proteins from 24 h supernatants
(Fig. 5a), suggesting a shifted balance between anteriorizing and
posteriorizing factors in the supernatant collected at the later
stage.
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Secretome analysis from 7.5/1 and 7.5/3 by tandem mass
spectometry (MS/MS) identiﬁed 269 proteins allocated to the gene
ontology term ‘extracellular space’ (Fig. 5c, entire list of proteins
can be found as Supplementary Data 1). DKK1 was the highest
enriched factor in 7.5/3 (Fig. 5b), conﬁrming the protein array and
western blotting data (Supplementary Fig. 5b,c). Notably, LEFTY1,
a component of NODAL signalling, was detected among the
highest-enriched proteins at 7.5/1 (Fig. 5b) and readily detectable
in the 6 h secretome (Fig. 5c). In all, 25 proteins were ‘24 h-
secretome exclusive’, including CER1 (Fig. 5c), consistent with
CER1 upregulation in response to CHIR (Supplementary Fig. 5a).
Since CER1 and LEFTY1 were described to restrict posterior
progression of PS in mouse embryos40, we tested their knock-
down at most anteriorizing conditions, the 7.5/1 cornerstone.
Compared with scrambled siRNA treatment, a 2.6-fold increase
in NKX2.5-GFPþ (from 24.3±7.5 to 64.4±14.5%; Fig. 5d) was
observed for combined knockdowns, whereby single siRNA
treatments resulted in partial GFP upregulation. In line with this,
the dual knockdown resulted in an increase of MIXL1þ from
38.7±8.4 to 71.0±2.3% after 24 h of CHIR treatment (Fig. 5e).
Vice versa, differentiation progression was anteriorized by
concomitant addition of recombinant LEFTY1 and CER1 to the
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most posterior condition (15/3) as indicated by the decrease of
MIXL1þ after 24 h from 70.8±5.6 to 44.5±7.3% (Fig. 5f). This
was further supported by partial rescue of the cardiac differen-
tiation at 15/3 by addition of LEFTY1 or CER1, respectively
(Supplementary Fig. 5j).
Together, this suggests a decisive role of LEFTY1 and CER1 in
the paracrine milieu, which is accountable for the anteriorizing
activity of high BCD, thereby delaying PS progression at 7.5/1
and 15/1.
Duration of CHIR/BCD treatment controls PS progression. To
investigate the time-dependence in this process, CHIR/BCD
treatment was prolonged from 24 to 48 h at 7.5/1. Signiﬁcant
NKX2.5-GFPþ increase from 7.4±2.0 to 56.8±3.5% (Fig. 5g)
suggests PS progression by prolonged incubation, thereby
apparently shifting deﬁnitive endoderm speciﬁcation of 7.5/1
after 24 h towards cardiomyogenesis after 48 h. Conversely,
reducing CHIR/BCD incubation from 24 to 18 h at 15/3 increased
NKX2.5-GFPþ from 46.3±2.3 to 71.08±4.7% (Fig. 5h). This
ﬁnding correlates with time-dependent reduction of PS progres-
sion at 15/3 from PSM towards the anterior PCM. To substantiate
the time-dependent context, MIXL1-GFP expression, represent-
ing an informative marker of PS progression (Fig. 2d,e), was
monitored over 48 h at all four cornerstones. Condition-speciﬁc
expression kinetics (Fig. 5i) revealed that continuous MIXL1
upregulation occurred at all conditions, suggesting that in prin-
ciple any distinct PS positioning can be achieved at any corner-
stone by respective timing. Relative MILX1 levels speciﬁc to 7.5/3
and 15/1 at 24 h (representative of PCM speciﬁcation in our
experiments) are readily achieved within B18 h at 15/3 but only
after 430 h at 7.5/1. These ﬁndings, which are in good correla-
tion with the independent cardiomyogenic analysis in Fig. 5g,h,
are summarized in a resulting model in Fig. 5j.
Discussion
By kick-starting the process only by CHIR, recent studies have
established directed hPSC differentiation into multiple lineages,
including deﬁnitive endoderm41,42 and deﬁnitive endoderm-
derived hepatocytes43, PCM-derived cardiomyocytes7,17,18,44
and endothelial progenitors45, as well as PSM-derived
chondrocytes28 and skeletal myoblast progenitors27. Moreover,
efﬁcient cardiomyogenesis was achieved at CHIR concentrations
ranging from 5 to 15mM (refs 7,17,18,44), notably overlapping
with 3–5mM used for deﬁnitive endoderm 41–43 and 6–10mM for
PSM derivatives27,28.
But how can glycogen synthase kinase 3 beta (GSK3)
inhibition determine such lineage variety, yet at broadly over-
lapping CHIR concentrations? Applying CHIR, Mendjan et al.28
showed that hPSCs are not turned into multipotent PS
progenitors maintaining prolonged lineage plasticity. Instead, a
restricted PS model was favoured suggesting that cells are readily
primed into restricted fates along a PS-like axis within 48 h of
differentiation28. Here, using cardiogenesis as central reference
point of anteroposterior speciﬁcation, we conﬁrm the restricted
PS model notably showing that distinct cell priming is readily
established at 24 h of CHIR treatment; at the secretome level
decisive conditions are present at 6 h and differential -catenin
activity can be measured as early as 2–3 h post CHIR
supplementation (Supplementary Fig. 4).
One key aim of our study was to conclusively elucidate how the
BCD deﬂects CHIR-induced hPSC priming. We show that
increasing CHIR progressively pushes PS priming towards
posterior fates; omitting CHIR leaves cells ‘uninstructed’ and
fading. In contrast, elevating the BCD restricts PS progression.
Thus, at any given CHIR dose and incubation time, relatively
higher BCD results in more anterior cell fate determination. This
raises the question of how this effect is mediated.
Extra media changes and swapping enriched protein samples
from the supernatants of opposing cornerstone conditions
strongly suggest that the BCD effect is mediated by paracrine
factors. Despite the overall complexity of these secretomes, we
showed that accumulation of individual factors is highly
differential and not merely following a simple linear correlation
with the BCD.
Two observations forced our attention on released factors
expressed in hPSCs ahead of differentiation. First, medium
refreshment after 6 h induced posteriorization suggesting very
early accumulation of anteriorizing factor(s) depleted by the
medium change. Second, secreted factors from 7.5/1 (high BCD,
most anteriorizing conditions) collected at 6 h resulted in
anteriorization of 15/3 (most posteriorizing condition). In
contrast, the 7.5/1 secretome collected at 24 h did not induce
anteriorization. This conﬁrms the early accumulation of ante-
riorizing factors at high BCD. Moreover, it highlights the
dynamic changes of the paracrine milieu not only in between
different cornerstone conditions but also within the same
condition throughout the ﬁrst 24 h.
Secretome analysis revealed that the NODAL signalling
antagonists, TGF family member LEFTY1 was among the most
prominently accumulated proteins at high BCD and readily
detected in secretome samples at 6 h (Fig. 5b,c). LEFTY1
knockdown resulted in posteriorization of the 7.5/1 cornerstone
(Fig. 5d), suggesting that LEFTY1 accumulation is a key source of
anteriorizing activity along rising BCD, thereby antagonizing
progression of CHIR-triggered differentiation. Recently, single-
cell RNA sequencing of the human blastocyst revealed that
LEFTY1, together with other key components of the TGF
signalling, is enriched in the human epiblast46. TGF signalling
was found to control NANOG expression in epiblast cells
revealing pathways’ requirement in pluripotency, whereby
conservation of pluripotency control between the human
embryo and hESC was highlighted46. However, secretome
analysis in our study conﬁrmed accumulation of another
NODAL antagonist, CER1, at high BCD conditions in 24 h
secretome samples comparing 7.5/1 versus 7.5/3 (Fig. 5b,c) in line
with factors’ upregulation at the RNA level (Supplementary
Fig. 5). Equivalent to LEFTY1, knockdown of CER1 also resulted
in posteriorization, which was additive to the effect of LEFTY1
reduction in double-knockdown experiments (Fig. 5d). Besser47
demonstrated regulatory crosstalk between WNT and TGF
signalling in hESCs. The study suggests that secreted WNTs
downstream of GSK3 inhibition upregulate NODAL signalling,
inducing activation of the ALK4/5/7 and SMAD 2/3 branch of the
pathway, notably counteracted by LEFTY1 and two proteins.
Moreover, ﬁndings by Besser suggest CER1 as a potential
inhibitor of the SMAD 1/5/8 branch of the TGF pathway,
thus counteracting pathways’ activation via secreted BMP
agonists. By these mechanisms LEFTIES and CER1 act in
parallel and in conjunction as retarder of hESC differen-
tiation47. This is in good agreement with our results at the
earliest steps of differentiation, showing decelerated progression
of posterior PS priming by LEFTY1 and CER1 supplementation
(Fig. 5f), likely acting by antagonizing the accelerating signals of
WNT and BMP pathway agonists.
Interestingly, a study by Hough et al.48 identiﬁed CER1 and
LEFTY1 as key candidates contributing to the heterogeneity in
hPSC cultures, which is another hint regarding their pivotal role
at the edge of pluripotency versus differentiation.
Our study has substantial practical consequences. It provides a
plausible, mechanistic explanation for how a speciﬁc CHIR
concentration, without co-supplementation of other factors, can
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induce hPSC differentiation into entirely different lineages by
means of BCD and time modulation, as graphically depicted in
Fig. 6. Reverse, we highlight the utmost importance of providing
detailed experimental information on the BCD, which is usually
not accounted for in most publications. Notably, despite showing
relevance to any culture format, using a monolayer-based
expansion/differentiation platform might be less sensitive regard-
ing the BCD. Irrespective of the seeded cell number, relatively
similar cell densities are typically achieved (per well or ﬂask) after
some days of culture in 2D, simply due to surface restrictions.
Subsequently, by applying a deﬁned medium volume for
differentiation and closely monitoring timing of CHIR exposure,
inter-experimental and trans-laboratory reproducibility in 2D is
facilitated; but edge-effects at the rim of a well or ﬂask have been
noted by us and others49.
The consequences for hPSC culture and differentiation in 3D
suspension are considerably more drastic. Suspension culture
technology strongly facilitates process scale-up, including transi-
tion into stirred bioreactors4,50–53. However, control of the cell
density is more critical in 3D since no surface-limited restriction
exist. Moreover, we showed that transition from monolayer to
matrix-free hPSC suspension culture is accompanied by district
WNT pathway modulations at the interplay of -catenin and
E-cadherin54. In addition, elevated expression of LEFTY1 at the
gene and protein level was observed without notable impact on
pluripotency54. In light of the current study, such culture platform-
dependent cellular and molecular changes suggest mayor
adaptation requirements for the transition of directed lineage
differentiation protocols from 2D to 3D. Furthermore, modulating
hPSC aggregate formation in 3D ahead of differentiation, for
example, by the inoculation density, stirring conditions and
process feeding patterns, likely shapes the secretome; variations
of which may underlie variations in lineage differentiation, which
we have recently postulated in a study on hPSC-cardiomyocyte
production in a stirred bioreactor17.
Another important prediction from the present study is that to
ensure successful differentiation into a desired lineage at higher
cell density, for example, to improve cell yields and process
efﬁciency in a restricted culture format, will require a higher
CHIR concentration when the incubation time is ﬁxed. Notably,
however, incubation timing becomes even more critical at higher
CHIR concentrations, as it accelerates progression of PS priming.
In summary, our study provides a novel mechanistic and
predictive understanding of the earliest stages of mesendodermal
priming of hPSCs, promotes better experimental control of these
processes and supports more rational translation into alternative
culture conditions.
Methods
hPSC culture. HES3 NKX2-5eGFP/w (ref. 19), HES3 MIXLeGFP/w (ref. 23),
hCBiPS2 (CBiPS)55, HSC_F1285_T-iPS2 (HSCiPS)49 and hHSC_F1488_SeV-iPS2
(nt-iPS; this study) were maintained under standard conditions on irradiated
mouse embryonic ﬁbroblasts (MEFs). hHSC_Iso4_ADCF_SeV-iPS2 (animal-
derived component-free conditions (ADCF) nt-iPS; this study) were maintained in
E8 medium on Synthemax-coated culture plates. Before differentiation, cells were
expanded for at least three passages under feeder-free conditions on geltrex-coated
tissue culture ﬂasks (TPP) in MEF-conditioned medium, mTeSR1 (Stem Cell
Technologies) or E8, and passaged at 5 104 cm 2 using accutase (PAA). Cell
lines have been karyotyped and were regularly tested for mycoplasma using
MycoAlert detection kit (Lonza).
Generation and characterization of non-transgenic iPSCs without or with
animal-derived component-free conditions. A total of 200,000 cord blood
CD34þ haematopoietic stem cells (either kindly provided by Vita34 or isolated
and cultivated under animal-component-free conditions) were transduced with
CytoTuneTM-iPS Sendai Reprogramming Kit (Invitrogen) at 37 C for 24 h in
haematopoietic stem cell medium or ADCF-haematopoietic stem cell medium
(IMDM, 10% fetal bovine serum, 100 ngml 1 interleukin-3, SCF, Flt-3 and TPO;
all from Peprotec) or Stem-Span-ACF-Medium (Stem Cell Technologies;
containing: 8 mgml 1 polybrene). To reduce residual virus vectors, cells were
centrifuged and reseeded in fresh medium the next day. Cells were transferred onto
mitotically inactivated MEFs or Corning Synthemax II-SC Subtrate (Corning)-
coated culture plates 4 days post transduction. On day 5, medium was changed to
PSC medium containing Knockout DMEM, serum replacement (20%), non-
essential amino acids (1%), L-glutamine (0,1%), b-mercaptoethanol (0.0025%,
all from Invitrogen) and bFGF (20 ngml 1, provided by Leibniz University
Hannover, Institute of Technical Chemistry), or TeSR-E7 medium (Stem Cell
Technologies). Single emerging iPSC clones were mechanically transferred onto
fresh feeder layers in PSC medium between days 9 and 20 or onto Synthemax-
coated plates on day 14 in TeSR-E8 (Stem Cell Technologies) and further
expanded.
For immunocytology, cells were ﬁxed with 4% paraformaldehdye and stained by
standard protocols using antibodies speciﬁc to OCT4 (1:100, Santa Cruz
Biotechologie), NANOG (1:500, Abcam), TRA-1-60 (1:100, Abcam), SSEA-3 and
SSEA-4 (1:100 and 1:70, Iowa Hybridoma Bank). To test multi-lineage
differentiation, cell were culture in DMEM plus 10% fetal bovine serum for up to
20 days followed by staining with antibodies speciﬁc to Troponin T (1:100, Thermo
Scientiﬁc), Sarcomeric-a-Actinin (1:800, Sigma), a-Fetoprotein and Sox17
(1:300 and 1:200, both R&D Systems), Desmin (1:20, Progen Biotechnik), and
b-3-Tubulin (1:400, Upstate). Appropriate secondary antibodies Cy2-labelled
donkey anti-mouse IgG, Cy3-labelled donkey anti-mouse IgG or donkey anti-
mouse IgM (1:200, Jackson Immunoresearch Laboratories) were applied followed
by counterstaining with 4,6-diamidino-2-phenylindole and analysis with an Axio
Observer A1 microscope (Carl Zeiss).
hPSC differentiation. Conﬂuent, feeder-free hPSCs were detached using accutase
and inoculated as single cells at 3.3 105 cells per ml in 1.5ml mTeSR1 supple-
mented with Rho-Kinase inhibitor Y-27632 (10 mM)56 in suspension culture 12-
well plates (Greiner) for aggregate-based differentiation, or at 2.66 105 cells per
ml in 1.5ml on geltrex-coated (Life Technologies) plates (Nunc) for monolayer-
based differentiation. A volume of 1ml mTeSR medium was refreshed on days  2
and  1. Differentiation of formed aggregates was initiated (day 0) by changing
medium to RPMI 1640 supplemented with B27 without insulin (1%, Life
Technologies). During the ﬁrst 24 h of differentiation, CHIR was added as
indicated at concentrations of 5–15 mM in a medium volume of 1–3ml. Thereafter,
cells were kept in 1.5ml medium volume, unless otherwise noted. On day 3, IWP2
(5 mM, Tocris) was added for 48 h. Aggregates were kept in RPMI 1640 containing
B27 from day 7–10.
Additional growth factors and small molecules were used at following
concentrations: bFGF (10 ngml 1)57; Activin A (6 ngml 1); BMP2
(1–100 ngml 1, both Peprotech); dorsomorphin (0.5–2 mM); forskolin (10 mM);
insulin (1–20 mgml 1); LEFTY1 (100–200 ngml 1, all Sigma); BMP4
(5 ngml 1); SFRP1 (0.1–1 mgml 1); BMPER (0.5–50 mgml 1, all R&D Systems);
Cer1 (1–10 mgml 1, Erik Martinez-Hackert); IWR-1 (4 mM, Stemgent); and
WAY-262611 (1 mM, Merck Millipore). CHIR99021 was kindly provided by the
Institute of Organic Chemistry, Hannover.
Medium enrichment (Amicon). Differentiation was induced using CHIR as
described above. Supernatant was collected after 6 and 24 h, and subsequently
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Figure 6 | Summary of decisive factors in PS patterning revealed in this
study. The four cornerstone conditions investigated in this study result in
distinct progression of the hPSCs during exit of pluripotency. Depending on
the level of CHIR (WNT pathway) stimulation and the BCD, primitive
streak-like patterning along the anteroposterior axis occurs that ultimately
determine cell fate into prospective deﬁnitive endoderm, cardiac mesoderm
and PSM. WNT (CHIR) and BMP signalling act as main driver of PS
progression over time, while cell-borne factors (LEFTY1 and CER1)
antagonize the progression of the streak formation depending on the BCDs.
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enriched by centrifugation at 4,500g for 15–20min using centrifugal ﬁlter tubes
(Amicon). The enriched medium was stored at  20 C or directly added to
experimental conditions as indicated.
Small interfering RNA. Single-cell hPSCs were seeded on geltrex-coated plates at
4.5 105 cells per cm2 in E8 medium supplemented with Y-27632 (10 mM),
respective small interfering RNAs (siRNAs; 100 nM, Ambion Silencer Select pre-
designed) and Lipofectamine 3000 (0.75%, Invitrogen). AlexaFluor546-labelled
scrambled siRNA (Qiagen) and lipofectamine-only-treated cells were used as
controls. After 24 h cells were washed with PBS and differentiation was performed
as described above. The sequences for CER1 and LEFTY1 were 50-ACCACU
UCAUGUUCAGAAAtt-30 and 50-GCUCUGUGCUCUCUAGUGAtt-30 ,
respectively.
Flow cytometry. Cells were dissociated using collagenase B (1mgml 1, Roche)
for 5–45min at 37 C (ref. 2). For staining of cardiac markers, 1.5 105 cells were
ﬁxed and permeabilized according to the manufacturer’s instructions (Fix & Perm;
An der Grub). For other intracellular staining, cells were ﬁxed and permeabilized
by incubation in cold methanol (90%) for 15min. Anti-cardiac Troponin T
(1:200, clone 13-11, Thermo Scientiﬁc), anti-sarcomeric a-actinin (1:800, EA53,
Sigma-Aldrich), anti-myosin heavy chain a (1:20, MF20, Hybridoma Bank),
anti-T-brachyury (1:50, N-19, Santa Cruz), anti-vimentin, anti-CDX2, anti-TRA-1-
60 (all 1:100, EPR3776, AMT28, TRA-1-60, respectively, Abcam), SSEA3, SSEA4
(1:100, MC-631 and MC-813-70, respectively, Hybridoma Bank) and respective
isotype controls (DAKO) were detected using appropriate Cy3- or Cy5-conjugated
antibodies (1:200; Jackson ImmunoResearch). EpCAM-FITC (1:100; EBA-1),
NCAM-PE-CF594 (1:50; B159, both BD biosciences), CD90-APC (1:100, 5E10,
Life Technologies), cKIT-PE and CXCR4-APC (1:100; both eBioscience) were
incubated for 30min at 4 C. Data were acquired on an Accuri C6 ﬂow cytometer
(BD Biosciences) and analysed using FlowJo software (Treestar, Ashland, USA).
Western blotting. SDS–PAGE gels were blotted onto nitrocellulose membranes
and incubated with the respective primary antibodies (anti-SFRP1, Cell Signaling
Technologies, clone D5A7, 1:500; anti-DKK1, R&D Systems, AF1096, 1:2,000).
As secondary antibodies ﬂuorescently labelled IRDye800 and 680 (LI-COR,
Lincoln, NE) were used. Fluorescence detection was performed using an Odyssey
infrared imaging system (LI-COR) and blots were further analysed using the
Odyssey v3.0 software (LI-COR).
Protein array. A customized human Quantibody protein array (QAH-CUST,
Ho¨lzel Diagnostika) covering 40 different factors was performed according to the
manufacturer’s instruction and scanned on an Axon 4000B. Data were extracted
using GenePix and processed using Q-Analyzer v8.40.4.
Microarray. A customized whole-human genome oligo microarray 4 44 K v2
(design ID 054261, Agilent Technologies) covering roughly 26,000 human
transcripts was hybridized with Cy3-labelled cRNA synthesized by the
‘Quick Amp Labeling kit, One Color’ #5190-0442, Agilent Technologies. cRNA
fragmentation, hybridization and washing steps were carried out exactly as
recommended in the ‘One-Color Microarray-Based Gene Expression Analysis
Protocol V5.7’. A unit of 1,650 ng of each labelled cRNA population were used for
hybridization.
Slides were scanned on the Agilent Micro Array Scanner G2565CA (pixel
resolution 3 mm, bit depth 20). Data extraction was performed with the ‘Feature
Extraction Software V10.7.3.1’ using a modiﬁed version of the recommended
default extraction protocol ﬁle ‘GE1_107_Sep09.xml’ in which the minimal number
of replicates to calculate Population Outliers was set to 5. Data were analysed using
Qlucore Omics Explorer 3.0 (Qlucore AB, Lund, Sweden) for principal component
analysis and heatmap generation. The RCUTAS ﬁlter tool (Research Core Unit
Transcriptomics of Hannover Medical School) was used for the identiﬁcation of
42- and 45-fold regulated genes. Gene ontology analysis of 45-fold regulated
genes was performed using webgestalt software (http://bioinfo.vanderbilt.edu/)58.
The microarray data were deposited under accession number E-MTAB-5051 in the
ArrayExpress database (www.ebi.ac.uk/arrayexpress).
Ultra-performance liquid chromatography-based quantiﬁcation of CHIR99021.
A volume of 5ml of each sample were injected on a ultra-performance liquid
chromatography (UPLC) column (35 C column temperature, nuclear gravity,
50 2mm, 1.8mm, Macherey&Nagel, Germany) and analysed by UPLC–ESI–MS
(Acquity UPLC coupled with Q-Tof premier electrospray ionization (ESI)–MS,
software Masslynx 4.1, all components by Waters, UK) using a linear gradient of
solvent A (double distilled water; 0.1% formic acid) and solvent B (Fluka methanol
LC–MS CHROMASOLV; 0.1% formic acid): 0min (95% A and 5% B); 2.5min (5% A
and 95% B); 6.5min (5% A and 95% B); 6.6min (95% A and 5% B); and 8min (95%
A and 5% B, end of run) at a ﬂow rate of 400mlmin 1. CHIR99021 was detected
with a retention time of 1.69–1.99min by ESI–MS (3kV capillary voltage, 250 C
desolvation temperature and 650 l h 1 nitrogen as desolvation gas) as positive-
charged ion (MþHþ ). For quantiﬁcation, the selected ion chromatogram for the
mass range 464.5–465.5Da (MþHþ ) was generated and the signal at the proposed
retention time was integrated.
LC–MS/MS and automated MS data analysis. Secreted proteins were
precipitated from cell culture supernatants applying a carrier-assisted tri-
chloroacetic acid precipitation59 and subsequently separated by SDS–PAGE. Each
gel lane was cut into small pieces that were subjected to tryptic digestion according
to standard procedures60 (Supplementary Fig. 7). As described before54 peptides
were extracted, separated and analysed by reversed-phase chromatography using a
nano-ﬂow ultra-high-pressure liquid chromatography system (RSLC, Thermo
Fisher Scientiﬁc) coupled online to an LTQ-Orbitrap Velos mass spectrometer
(Thermo Fisher Scientiﬁc). For RSLC, peptides were trapped on a trapping column
(3 mm C18 particle, 2 cm length, 75 mm inner diameter, Acclaim PepMap, Thermo
Fisher Scientiﬁc) and separated using a reversed-phase separating column (2 mm
C18 particle, 50 cm length, 75 mm inner diameter, Acclaim PepMap, Thermo Fisher
Scientiﬁc). Peptide elution was performed with a multi-step binary gradient: linear
gradient of buffer B (80% acetonitrile (ACN) and 0.1% formic acid) in buffer A
(0.1% formic acid) from 4 to 25% in 115min, 25 to 50% in 25min, 50 to 90% in
5min, 90% B for 10min and switched to 4% B within 30min for reconditioning of
the column at a ﬂow rate of 250mlmin 1 and a column temperature of 45 C. For
MS, overview scans were acquired at a resolution of 60,000 (m/z¼ 400) in the mass
range of m/z 300–1,600, and the 10 most intensive two- and threefold charged ions
were fragmented by collision-induced fragmentation at an activation time of 10ms
and an activation Q of 0.250 in the LTQ. Fragment ion spectra were recorded in
the LTQ at a normal scan rate and stored as centroid m/z pairs. Raw data were
processed with the MaxQuant proteomics software suit61 version 1.5.0.22.
Peak lists were searched against the human International uniprot protein
sequence database (uniprot-homoþ sapiens) downloaded on 09 July 2015 at
www.uniprot.org at a false discovery rate of 1%. Proteins marked as ‘only identiﬁed
by site’, ‘reverse’ or ‘contaminant’ were removed from MaxQuant output ﬁles.
Quantitative comparison between different samples was performed based on
label-free quantiﬁcation intensities calculated by MaxQuant. The raw data were
deposited to the ProteomeXchange Consortium via the PRIDE partner repository
(www.ebi.ac.uk/pride) with the data set identiﬁer PXD004874. The processed data
are listed in Supplementary Data 1.
b-catenin suspension bead array-based assay. Cells were collected by
centrifugation at 2,000 r.c.f. at 4 C. Cell homogenization was performed under
native conditions in a 10-fold volume of lysis buffer (150mM NaCl, 50mM Tris
(pH 7.4), 1% Triton X-100, 1 Complete (Roche), 1 Phosphatase Inhibitor
Cocktail I and II (SIGMA-Aldrich), and Benzonase (2.5 units per ml, Novagen)).
Homogenates were incubated for 1 h on ice before insoluble cell fragments were
separated by centrifugation (20min, 4 C, 13,000 r.c.f.). Supernatants were analysed
by bead array-based sandwich immuoassays for total b-catenin, b-catenin phos-
phorylated at Ser33/ Ser37/Thr41, b-catenin phosphorylated at Ser45, b-catenin
phosphorylated at Ser552 and b-catenin phosphorylated at Ser 675 as described
earlier32. Free b-catenin was investigated by bead array-based glutathione
S-transferase-pull-down assays using glutathione S-transferase fusion proteins
for b-catenin and Tcf (ICAT), transcription factor 4 (TCF4) and the cytoplasmic
domain of E-cadherin as baits32,33.
Statistics. All data are presented as mean±s.e.m. Unless otherwise noted,
statistical signiﬁcance was determined by one-way analysis of variance followed by
Bonferroni’s multiple comparison post-test. Statistical signiﬁcance was assigned as
indicated in the ﬁgure legends.
Data availability. The authors declare that all data supporting the ﬁndings
of this study are available within the article and its Supplementary Information
ﬁles or from the corresponding author on reasonable request. Microarray data
have been deposited in the ArrayExpress database under accession number
E-MTAB-5051. Raw data for LC–MS/MS have been deposited in Proteo-
meXchange Consortium via the PRIDE partner repository under accession code
PXD004874.
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